CARS Antibody
Description
Definition and Mechanism of Anti-CAR Linker Antibodies
Anti-CAR linker antibodies are recombinant monoclonal antibodies designed to detect and analyze chimeric antigen receptor (CAR)-engineered immune cells, particularly those targeting cancer or autoimmune diseases. These antibodies bind to the linker sequences (e.g., G4S or Whitlow/218) between the variable heavy and light domains of single-chain variable fragment (scFv)-based CARs . Unlike antigen-specific detection reagents, they enable universal monitoring of CAR expression regardless of the target antigen, making them versatile tools for research and therapeutic development .
Key Features:
-
Target Agnostic: Detects any scFv-based CAR containing G4S or Whitlow linkers .
-
Applications: Flow cytometry, cell sorting, and in situ analysis of CAR+ cells .
Applications in CAR-T Therapy Development
Anti-CAR linker antibodies are integral to optimizing CAR-T cell therapies:
Advantages Over Conventional Detection Methods
Anti-CAR linker antibodies overcome limitations of antigen-specific reagents:
-
Universality: Detects CARs regardless of target antigen, reducing reagent development time .
-
Sensitivity: Bypasses interference from soluble antigens or competing immune responses .
-
Cost-Effectiveness: Eliminates the need for patient-specific reagents .
Challenges and Considerations
-
Off-Target Effects: Potential cross-reactivity with endogenous proteins (e.g., Whitlow linker shares homology with human proteins) .
-
Immunogenicity: Engineered Tregs expressing CARs may provoke anti-CAR immune responses, limiting persistence .
-
Standardization: Variability in linker sequences across CAR designs requires thorough validation .
Recent Research Highlights
-
Autoimmune Disease Models: Anti-CAR linker antibodies enabled tracking of CAAR-T cells targeting autoreactive B cells in pemphigus vulgaris .
-
Solid Tumors: Demonstrated utility in quantifying CAR-T infiltration and function in melanoma and glioblastoma .
-
Clinical Trials: Facilitated monitoring of CD19/CD20 CAR-T persistence in B-cell leukemia patients .
Future Directions
Product Specs
Target Background
- Four single nucleotide polymorphisms (SNPs) of CARS were significantly associated with gastric cancer risk in both the discovery and validation stages. PMID: 28409418
- The risk (G and C) and non-risk (C and T) allele frequencies of the SNPs at the rs1888747 and rs739401 loci of FRMD3 and CARS, respectively, did not differ significantly between diabetics with and without nephropathy (P > 0.05). PMID: 26909942
- Loss of CARS suppresses ferroptosis induced by erastin, an inhibitor of the cystine-glutamate antiporter known as system xc(-). PMID: 26184909
- CARS is a novel fusion partner of anaplastic lymphoma kinase in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor cases. PMID: 12112524
- The specificity of anticodon recognition by human CysRS is higher than that of its bacterial counterparts. PMID: 17303165
